Lupin Ltd — Earnings Release 2021

May 12, 2021

May 12, 2021

==> picture [79 x 93] intentionally omitted <==

 BSE Limited

Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001.

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051.

Dear Sir/Madam,

Sub: Information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

Pursuant to Regulation 30(2) read with Schedule III Part A Para A(4)(h) of the Listing Regulations, enclosed is a Press Release, inter alia covering the audited (standalone and consolidated) financial results of the Company for the year ended March 31, 2021.

Kindly note the above and take on record.

Thanking you,

For LUPIN LIMITED

Rajvardhan

Vishnu Satam

Digitally signed by Rajvardhan Vishnu Satam DN: c=IN, o=Personal, 2.5.4.20=e8a002ede68da3b7e41e01d21c2b9062761a29a5f0049 1762a5ac549cb034cae, postalCode=400104, st=Maharashtra, serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f72 6cdb67a2ff09c4242771b2a, cn=Rajvardhan Vishnu Satam Date: 2021.05.12 23:51:21 +05'30'

R. V. SATAM COMPANY SECRETARY (ACS-11973)

Encl.: a/a

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

Press Release

==> picture [68 x 70] intentionally omitted <==

Lupin FY2021 Results

Mumbai, May 12, 2021 : Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter and fiscal year ending March 31, 2021. These audited results were taken on record by the Board of Directors at a meeting held today. The Board recommended a dividend of 325%.

==> picture [562 x 25] intentionally omitted <==

----- Start of picture text -----

Financial Highlights (from Continuing Operations) – Consolidated IND-AS
----- End of picture text -----

							Amt	in INR mn
Particulars			Quarter				Full Year
	Q4 FY21	Q3 FY21	QoQ Growth %	Q4 FY20	YoY Growth %	FY21	FY20	YoY Growth %
Sales	37,593	39,173	↓ 4.0%	37,910	↓ 0.8%	149,270	151,428	↓ 1.4%
EBITDA before forex & other income	7,075	8,064	↓ 12.3%	5,237	↑ 35.1%	26,578	23,633	↑ 12.5%
EBITDA Margin(%)	18.8%	20.6%	↓180 bps	13.8%	↑500 bps	17.8%	15.6%	↑220 bps
PBT before Exceptional items	5,182	5,247	↓ 1.2%	4,123	↑ 25.7%	16,751	15,054	↑ 11.3%
PBT after Exceptional Items	5,182	5,247	↓ 1.2%	4,954	NA	16,751	7,533	NA

– Income Statement highlights Q4 FY2021

• ❖ Gross Profit was INR 24,417 mn compared to INR 25,423 mn in Q3 FY2021, with gross profit margin of 65.0%

• ❖ EBIDTA adjusted for forex and other income was 18.8% of sales, compared to 18.6% in Q3FY2021 excluding the one-time settlement income forming part of other operating income

• ❖ Personnel cost was 17.0% of sales at INR 6,402 mn compared to INR 7,068 mn in Q3 FY2021

• ❖ Manufacturing and other expenses were 29.7% of sales at INR 11,178 mn compared to INR 11,569 mn in Q3 FY2021

• ❖ Investment in R&D for the quarter was INR 3,427 mn (9.1% of sales)

Balance Sheet highlights

• ❖ Operating working capital was INR 62,136 mn as on March 31, 2021

• ❖ Capital Expenditure for the quarter was INR 1,396 mn, and for the full year was INR 6,276 mn

• ❖ Net Debt as on March 31, 2021 stands at INR 6,626 mn

• ❖ Net Debt-Equity for the company stands at 0.05 as on March 31, 2021

Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, “We are happy that the journey to sustain margin improvement continues, despite a challenging environment. On the back of a strong ramp-up of inline products and meaningful new product launches, we are confident of a solid growth trajectory and continued margin expansion. Ensuring the safety of our employees while maintaining business continuity is a key priority at this time.”

Page 1 of 7

Press Release

==> picture [68 x 70] intentionally omitted <==

==> picture [543 x 25] intentionally omitted <==

----- Start of picture text -----

Consolidated Financial Results – Q4 FY2021
----- End of picture text -----

							Amt in INR mn	Amt in INR mn
Particulars	Q4 FY21	% of sales	Q3 FY2021	% of sales	QoQ Growth %	Q4 FY20	% of sales	YoY Growth %
Sales Other operating income	37,593 238	100.0% 0.6%	39,173 1,001	100.0% 2.6%	-4.0% -76.2%	37,910 547	100.0% 1.4%	-0.8% -56.5%
Total Revenue from operations	37,831	100.6%	40,174	102.6%	-5.8%	38,457	101.4%	-1.6%
Material cost	13,176	35.0%	13,750	35.1%	-4.2%	14,050	37.1%	-6.2%
Gross Profit (Excl. Other op. income)	24,417	65.0%	25,423	64.9%	-4.0%	23,860	62.9%	2.3%
Employee cost Manufacturing & Other expenses Other Income	6,402 11,178 582	17.0% 29.7% 1.5%	7,068 11,569 212	18.0% 29.5% 0.5%	-9.4% -3.4% 174.5%	7,635 11,519 2,086	20.1% 30.4% 5.5%	-16.1% -3.0% -72.1%
EBITDA	7,657	20.4%	7,999	20.4%	-4.3%	7,339	19.4%	4.3%
Depreciation, Amortization & Impairment Expense	2,157	5.7%	2,443	6.2%	-11.7%	2,142	5.7%	0.7%
EBIT	5,500	14.6%	5,556	14.2%	-1.0%	5,197	13.7%	5.8%
Finance cost	318	0.8%	309	0.8%	2.9%	1,074	2.8%	-70.4%
PBT before Exceptional items	5,182	13.8%	5,247	13.4%	-1.2%	4,123	10.9%	25.7%
Exceptional items1	-	0.0%	-	0.0%	NA	(831)	-2.2%	NA
PBT after Exceptional items	5,182	13.8%	5,247	13.4%	-1.2%	4,954	13.1%	4.6%
Tax2	540	1.4%	835	2.1%	-35.3%	1,051	2.8%	-48.6%
Profit after Tax	4,642	12.3%	4,412	11.3%	5.2%	3,903	10.3%	18.9%
(+) Share of Profit from JV (-) Non-Controlling Interest	2 40	0.0% 0.1%	2 31	0.0% 0.1%	0% 29.0%	10 17	0.0% 0.0%	-80% 135.3%
Profit/(Loss) for the period	4,604	12.2%	4,383	11.2%	5.0%	3,896	10.3%	18.2%

Page 2 of 7

Press Release

==> picture [68 x 70] intentionally omitted <==

==> picture [543 x 25] intentionally omitted <==

----- Start of picture text -----

Consolidated Financial Results - FY2021
----- End of picture text -----

Amt in INR mn

Particulars	FY2021	% of sales	FY2020	% of sales	YoY Growth %
Sales Other operating income	149,270 2,360	100.0% 1.6%	151,428 2,320	100.0% 1.5%	-1.4% 1.7%
Total Revenue from operations	151,630	101.6%	153,748	101.5%	-1.4%
Material cost	53,622	35.9%	54,306	35.9%	-1.3%
Gross Profit (Excl. Other op. income)	95,648	64.1%	97,122	64.1%	-1.5%
Employee cost Manufacturing & Other expenses Other Income	28,259 44,080 1,363	18.9% 29.5% 0.9%	29,868 46,025 4,837	19.7% 30.4% 3.2%	-5.4% -4.2% -71.8%
EBITDA	27,032	18.1%	28,386	18.7%	-4.8%
Depreciation, Amortization & Impairment Expense	8,874	5.9%	9,703	6.4%	-8.5%
EBIT	18,158	12.2%	18,683	12.3%	-2.8%
Finance cost	1,407	0.9%	3,629	2.4%	-61.2%
PBT before Exceptional items	16,751	11.2%	15,054	9.9%	11.3%
Exceptional items1	-	0.0%	7,521	5.0%	NA
PBT after Exceptional items	16,751	11.2%	7,533	5.0%	NA
Tax2	4,485	3.0%	11,571	7.6%	-61.2%
Profit after Tax	12,266	8.2%	(4,038)	-2.7%	NA
(+) Share of Profit from JV (-) Non-Controlling Interest	13 114	0.0% 0.1%	39 (4)	0.0% 0.0%
Net Profit from continuing operations	12,165	8.1%	(3,995)	-2.6%	NA
Profit/(Loss) from discontinued operations	0	NA	1,301	0.9%	NA
Profit/(Loss) for the period	12,165	8.1%	(2,694)	-1.8%	NA

Page 3 of 7

Press Release

==> picture [68 x 70] intentionally omitted <==

==> picture [543 x 25] intentionally omitted <==

----- Start of picture text -----

Sales Mix
----- End of picture text -----

Particulars	Q4 FY21	Q3 FY21	Growth QoQ	Q4 FY20	Growth YoY
North America India Growth Markets EMEA ROW	14,952 12,866 3,033 3,749 437	14,424 13,669 3,314 3,272 1,056	3.7% -5.9% -8.5% 14.6% -58.5%	15,791 11,920 2,800 3,650 463	-5.3% 7.9% 8.3% 2.7% -5.5%
Total Formulations	**35,037 **	35,735	-2.0%	34,624	1.2%
API	2,556	3,438	-25.6%	3,286	-22.2%
Consolidated Sales	37,593	39,173	-4.0%	37,910	-0.8%

==> picture [133 x 10] intentionally omitted <==

----- Start of picture text -----

Q4 FY2021 Product Sales Mix
----- End of picture text -----

==> picture [141 x 126] intentionally omitted <==

----- Start of picture text -----

1% [7%]
10%
40%
8%
34%
----- End of picture text -----

North America India Growth Markets EMEA ROW API

Particulars	FY21	FY20	Growth YoY
North America India Growth Markets EMEA ROW	55,520 52,712 11,964 12,781 2,470	58,212 51,385 12,212 12,364 2,815	-4.6% 2.6% -2.0% 3.4% -12.2%
Total Formulations	135,447	136,988	-1.1%
API	13,823	12,999	6.3%
Total Product Sales	149,270	149,987	-0.5%
NCE LicensingIncome	-	1,441	NA
Consolidated Sales	149,270	151,428	-1.4%

FY2021 Product Sales Mix

2%[9%] 9% 37% 8% 35% North America India Growth Markets EMEA ROW API

Page 4 of 7

Press Release

==> picture [68 x 70] intentionally omitted <==

z

North America

Lupin’s North America sales for FY2021 were INR 55,520 mn compared to INR 58,212 mn in FY 2020; accounting for 37% of Lupin’s global sales. Q4 FY2021 sales were INR 14,952 mn, up 3.7% compared to INR 14,424 mn during Q3 FY2021 and sales of INR 15,791 mn during Q4 FY2020.

• ❖ For the U.S. market, FY2021 sales were USD 720 mn compared to USD 800 mn in FY2020

• ❖ Q4 FY2021 sales were USD 195 mn compared to USD 188 mn during Q3 FY2021 and USD 212 mn during Q4 FY2020

• ❖ The Company filed 9 ANDAs during the quarter and received 6 ANDA approval from the U.S. FDA

• ❖ The Company launched 3 products during the quarter in the US market. The Company now has 168 products in the U.S. generics market.

• ❖ Lupin continues to be the 3[rd] largest pharmaceutical player in both U.S. generic market and US total market by prescriptions (IQVIA MAT March 2021)

• ❖ Lupin is now the market leader in 53 products in the U.S. generics market and amongst the Top 3 in 122 of its marketed products (market share by prescriptions, IQVIA March 2021)

India

Lupin’s India formulation sales for FY2021 were INR 52,712 mn, up 2.6% as compared to INR 51,385 mn in FY2020; accounting for 35% of Lupin’s global sales. Q4 FY2021 sales were INR 12,866 mn, compared to sales of INR 13,669 mn during Q3 FY2021 and up 7.9% compared to sales of INR 11,920 mn during Q4 FY2020.

Lupin is the 6[th] largest company in the Indian Pharmaceutical Market (IQVIA MAT March 2021).

Growth Markets (LATAM and APAC)

Lupin’s LATAM & APAC regions together form its Growth Markets. Growth Markets sales for FY2021 were INR 11,964 mn, compared to INR 12,212 mn in FY2020; accounting for 8% of Lupin’s global sales. Q4 FY2021 sales were INR 3,033 mn, compared to sales of INR 3,314 mn during Q3 FY2021 and up 8.3% as compared to sales of INR 2,800 mn during Q4 FY2020.

Lupin’s Brazil sales were BRL 239 mn for FY2021, compared to a sales of BRL 177 mn for FY2020. Q4 FY2021 sales were BRL 59 mn, compared to BRL 66 mn during Q3 FY2021 and BRL 37 mn during Q4 FY2020.

Lupin’s Mexico sales were MXN 621 mn for FY2021, compared to a sales of MXN 691 mn for FY2020. Q4 FY2021 sales were MXN 154 mn, compared to MXN 188 mn during Q3 FY2021 and MXN 171 mn during Q4 FY2020.

Lupin’s Philippines sales were PHP 1,388 mn for FY2021, compared to a sales of PHP 1,874 mn for FY2020. Q4 FY2021 sales were PHP 402 mn, compared to PHP 367 mn during Q3 FY2021 and PHP 522 mn during Q4 FY2020.

Lupin’s Australia sales were AUD 57 mn for FY2021, compared to a sales of AUD 48 mn for FY2020. Q4 FY2021 sales were AUD 14.2 mn, compared to AUD 15.7 mn during Q3 FY2021 and AUD 13.0 mn during Q4 FY2020.

Page 5 of 7

Press Release

==> picture [68 x 70] intentionally omitted <==

Europe, Middle-East and Africa (EMEA)

Lupin’s EMEA sales for FY2021 were INR 12,781 mn, up 3.4% as compared to INR 12,364 mn in FY 2020; accounting for 9% of Lupin’s global sales. Q4 FY2021 sales were INR 3,749 mn, up 14.6% compared to sales of INR 3,272 mn during Q3 FY2021 and up 2.7% as compared to sales of INR 3,650 mn during Q4 FY2020.

Lupin’s South Africa sales were ZAR 1,295 mn for FY2021, compared to a sales of ZAR 1,219 mn for FY2020. Q4 FY2021 sales were ZAR 431 mn, compared to ZAR 323 mn during Q3 FY2021 and ZAR 374 mn during Q4 FY2020.

Lupin is the 4[th] largest generic player in the South African market by prescription (IQVIA February 2021).

Lupin’s Germany sales were EUR 29.2 mn for FY2021, compared to a sales of EUR 36.2 mn for FY2020. Q4 FY2021 sales were EUR 5.4 mn, compared to EUR 8.1 mn during Q3 FY2021 and EUR 9.3 mn during Q4 FY2020.

Global API

Lupin’s Global API sales for FY2021 were INR 13,823 mn, up 6.3% as compared to INR 12,999 mn in FY 2020; accounting for 9% of Lupin’s global sales. Q4 FY2021 sales were INR 2,556 mn, compared to sales of INR 3,438 mn during Q3 FY2021 and sales of INR 3,286 mn during Q4 FY2020.

Research and Development

Investment in R&D for continued operations amounted to INR 14,324 mn (9.6% of sales) for FY2021 and INR 3,427 mn (9.1% of sales) for Q4 FY2021.

Lupin received approval for 6 ANDA from the U.S. FDA during the quarter. Cumulative ANDA filings with the US FDA stood at 437 as of March 31, 2021, with the company having received 288 approvals to date.

The Company now has 45 First-to-Files (FTF) filings including 16 exclusive FTF opportunities. Cumulative DMF filings stand at 201 as of March 31, 2021.

Page 6 of 7

Press Release

==> picture [68 x 70] intentionally omitted <==

About Lupin Limited

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and MiddleEast regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. In FY2021, the Company invested 9.6% of its revenues on research and development.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information. Follow us on Twitter: https://twitter.com/LupinGlobal | LinkedIn: https://www.linkedin.com/company/lupin | Facebook: http://www.facebook.com/LupinWorld/

For further information or queries please contact –

Arvind Bothra Head – Investor Relations / Corporate M&A Email:arvindbothra@lupin.com Tel: +91-22 6640 8237	Shweta Munjal Head – Corporate Communications Email:shwetamunjal@lupin.com Tel: +91-22-6640 2532

Page 7 of 7